John Kellum
Pittsburgh, PANPI 1629042106
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $150,523 of the $200,089 with a category attached, or 75.2%. 21 manufacturers reported payments, led by Astute Medical, Inc. at 33.0% of the total. Reporting peaked in 2021 at $74,502 and has fallen 87.3% since, to $9,470 in 2025.
Across 128 payments — averaging $1563.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astute Medical, Inc.$66K
- Biomerieux Inc$34K
- Baxter Healthcare$21K
- Astellas Pharma Inc$18K
- Chugai Pharmaceutical Co., Ltd.$13K
- Nxstage Medical, Inc.$13K
- plus $35K from 15 others
Across 31 payments — averaging $30,674 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomerieux Inc$475K
- Astute Medical, Inc.$313K
- Baxter Healthcare$150K
- Astellas Pharma Inc$13K
What the payments were for
- Consulting fees$150,52375%
- Speaking & faculty fees$42,48521%
- Travel & lodging$5,5203%
- Food & beverage$1,5601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astute Medical, Inc. | 29 | $66,023 |
| Biomerieux Inc | 18 | $33,700 |
| Baxter Healthcare | 26 | $20,656 |
| Astellas Pharma Inc | 6 | $18,488 |
| Chugai Pharmaceutical Co., Ltd. | 9 | $13,360 |
| Nxstage Medical, Inc. | 15 | $13,045 |
| Astrazeneca UK Limited | 2 | $7,000 |
| Mallinckrodt Hospital Products Inc. | 2 | $6,860 |
| CSL Behring | 2 | $4,230 |
| AstraZeneca | 1 | $4,000 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $3,360 |
| Tanabe Pharma America, Inc. | 5 | $3,150 |
| GE HealthCare | 2 | $1,750 |
| Cochlear Ltd | 1 | $1,650 |
| Janssen Research & Development, LLC | 1 | $1,500 |
| Heron Therapeutics, Inc. | 1 | $470 |
| BD | 1 | $350 |
| Vantive US Healthcare LLC | 3 | $190 |
| La Jolla Pharmaceutical Company | 1 | $168 |
| Shionogi Inc | 1 | $120 |
| Roche Diagnostics Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEPHROCHECK TEST$48,649
- NEPHROCHECK Liquid Control Kit$30,489
- NEPHROCHECK$12,975
- System One$11,080
- Renal - Non Product Related$9,090
- Renal - Prismaflex System$4,000
- Renal - Acute$3,142
- Fluid Systems - Non Prod Related$2,531
- NXSTAGE SYSTEM ONE$1,750
- Non-Franchise (NOF) - NonProduct$1,708
- Nucleus$1,650
- Baha$1,650
- Renal - CRRT$1,407
- Non-Covered Product$1,050
- HTX-011$470
- HemoSphere$350
- Fetroja$120
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.